Compare Intel Corp (INTC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Novo Nordisk A/S — how do they compare? Intel Corp trades at $98.95 (market cap $492.85B), while Novo Nordisk A/S trades at $45.96 (market cap $207.85B). The key difference: Intel Corp is far larger — about 2.4× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| INTC | NVO | |
|---|---|---|
Market Cap | $492.85B | $207.85B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $63.98 |
52-Week Low | $21.81 | $35.29 |
Enterprise Value | $513.66B | $222.55B |
Dividend Yield | 2.24% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $97.52, down 4.06% today amid a $20 billion stock offering announcement. Despite recent earnings beats, the stock faces pressure from dilution concerns while showing strong revenue growth in data center and AI segments. Technical indicators are bullish on moving averages but neutral on oscillators, with key resistance at $100. Fundamentals reveal a mixed picture with negative net income margins but improving operational cash flow trends.
The outlook remains cautiously optimistic with a $116.67 analyst price target suggesting 20% upside, though execution risks in foundry losses and competitive pressures persist. Investors should weigh the growth potential in AI against near-term dilution and margin challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
